PMEF
BMRN icon

Point72 Middle East FZE’s BioMarin Pharmaceuticals BMRN Stock Holding History

Point72 Middle East FZE’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-33,204
Closed -$2.88M – 1477
2023
Q2 		$2.88M Buy
+33,204
New +$3.12M 0.08% 298

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Point72 Middle East FZE's BMRN Position: Q3 2023 in Review

Point72 Middle East FZE sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 33,204 shares — an estimated $2.88M sold.

Point72 Middle East FZE first reported a position in BMRN in Q2 2023 and held it in 1 quarter. The position peaked at $2.88M in Q2 2023. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • Point72 Middle East FZE reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 33,204 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $2.88M.
  • Point72 Middle East FZE first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's BioMarin Pharmaceuticals position peaked at $2.88M in Q2 2023.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.